Nov 29, 2023 / 01:30PM GMT
Matthew Oliver O'Brien - Piper Sandler & Co., Research Division - MD & Senior Research Analyst
All right. Good morning, everybody. Thanks so much for joining us. Matt O'Brien. I cover med tech here at Piper. Tickled, very excited, lucky, fortunate, whatever adjective you want to use to have DexCom with us this morning.
From the company is Jeremy, who's the CFO of the company, Jeremy, thanks so much for coming out.
Jereme M. Sylvain - DexCom, Inc. - Executive VP, CFO & CAO
Thanks for having us. Thanks for being tickled.
Matthew Oliver O'Brien - Piper Sandler & Co., Research Division - MD & Senior Research Analyst
You bet. So maybe I'm going to get to the Q4 guide in a second. But just on the Q3 performance, that domestic results on a 2-year stack was as good as we've seen in a while, and that's -- everybody has been focused on domestic, domestic, domestic -- can you just talk a little bit about maybe just deconstruct where the strength came from on a 2-year
Dexcom Inc at Piper Sandler Healthcare Conference Transcript
Jan 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers